MarketInOut Stock Screener Log In | Sign Up
 

4D Molecular Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/25/2026 16:00
4D Molecular Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization874.52 mln
Float42.42 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

3418
Highly suspicious

1-Year Forecast

29.10
Transformational upside

Relative Strength

98 / 100
Top performer

Debt / Equity

0.10
Very low leverage

ROE

-41.57
Deeply negative

Business Description

4D Molecular Therapeutics is a late-stage biotech company based in Emeryville, California, with operations in the Netherlands, that develops gene therapy treatments using its proprietary vector discovery platform. Its most advanced therapy, 4D-150, targets retinal diseases such as wet age-related macular degeneration and diabetic macular edema by delivering long-lasting treatment through a single eye injection. The company has additional programs in earlier stages of development targeting cystic fibrosis, geographic atrophy, and a rare lung disease, and works in partnership with Otsuka Pharmaceutical.

Key Fundamentals

EPS-2.63
ROE-41.57
RPS1.43
ROIC-143
ROA-36.27
EBITDA, mln-189
EV / EBITDA-1.67
EV / EBIT-1.60
Revenue, mln92.01
EV / Revenue3.43

Financial Strength

Altman Z-Score3.82
Piotroski F-Score 3 / 9
Beneish M-Score3418
1-Year Target Price29.10
Short Ratio15.02
Short % of Float26.62

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.79% 87 / 100   
1 Month 51.45% 97 / 100   
2 Months 87.81% 98 / 100   
6 Months 56.11% 93 / 100   
1 Year 122% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us